Drug intelligence / Profile preview

Hysan Salinspray

Development stage: Unknown
Lead developer: URSAPHARM Arzneimittel
Administration: Intranasal

Overview

Hysan Salinspray (hysan® Salinspray) is a nasal spray medical device containing a 2.7% hypertonic sea salt solution (Maris Sal). Developed and manufactured by URSAPHARM Arzneimittel GmbH, it is indicated for the symptomatic relief of nasal congestion associated with acute nasopharyngitis (common cold) and acute sinusitis. The solution works via an osmotic mechanism, drawing excess water from the swollen nasal mucosa to reduce inflammation and liquefying thick secretions to facilitate drainage. It is free of preservatives and chemical additives, making it suitable for long-term use without the risk of habituation or rebound effects. It is approved for use in adults, children from 1 year of age, and during pregnancy and breastfeeding.

Brand names: hysan Salinspray
Other names: hysan Salinspray nasal spray

Beyond the preview

Go deeper on Hysan Salinspray.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hysan Salinspray.

Explore the full profile